Kelun-Biotech Reports Success in Phase III Trial for Sacituzumab Tirumotecan in Treating TNBC

Kelun-Biotech Reports Phase III Trial Success

Sichuan Kelun-Biotech Biopharmaceutical Company has made headlines today by announcing that the Phase III clinical trial, known as OptiTROP-Breast03, for their antibody drug conjugate (ADC) sacituzumab tirumotecan (also referred to as sac-TMT) has successfully met its primary endpoint of progression-free survival (PFS) in treating advanced triple-negative breast cancer (TNBC).

This trial focuses on patients suffering from unresectable locally recurrent or metastatic TNBC who had not previously undergone systemic therapy for advanced disease. The trial included a diverse patient pool, encompassing those with both PD-L1 positive and negative expressions. At this interim analysis, the data indicated a statistically significant and clinically meaningful enhancement in PFS compared to the standard chemotherapy administered at the discretion of the investigators.

The OptiTROP-Breast03 study is notable not only for its focus on PFS and overall survival (OS) but also for being the first of its kind to show positive results in a front-line treatment setting for TNBC. The safety profile of sac-TMT remained consistent with earlier studies, with no newly identified safety issues arising during the trial. The current trend suggests improved outcomes, although OS data remains in its early stages. Follow-up will continue as per established protocols, with more detailed evaluations slated for future analyses.

As a milestone, these interim results prompt the company to initiate discussions with China's National Medical Products Administration (NMPA) regarding future regulatory steps for sac-TMT. Previously, sac-TMT had been approved for use in patients who had undergone at least two rounds of therapy in advanced settings.

Kelun-Biotech’s foray into this realm of innovative treatment methods has not been without precedent. The company has already developed numerous other indications for sac-TMT, receiving approvals that span different cancer types. Moreover, it holds exclusive distribution rights to MSD (Merck & Co.) for the development and commercialization of sac-TMT outside Greater China, demonstrating its commitment to addressing primary healthcare needs globally.

In tandem with these advancements, a global Phase III study named TroFuse-011 is currently in progress, aimed at evaluating the efficacy of sac-TMT either as a monotherapy or combined with pembrolizumab for patients expressing low PD-L1 levels in TNBC. This highlights the company's broader commitment to understanding the multifaceted nature of TNBC and the pressing need for innovative therapies in this space.

The implications of this successful trial extend well beyond the immediate patient population and showcase the potential for ADCs in the treatment of solid tumors. By employing a unique bifunctional linker, sac-TMT ensures that targeted therapies are delivered directly into tumor cells, effectively maximizing drug efficacy while minimizing generalized toxicity.

Looking ahead, Kelun-Biotech hopes to leverage its findings to further consolidate its role in the innovative pharmaceutical landscape. As more data emerges from ongoing studies and regulatory discussions progress, the potential for sac-TMT to redefine treatment protocols for TNBC appears increasingly promising. With nine registrational clinical studies already initiated by this cutting-edge company, the future looks bright for Kelun-Biotech, patients, and the oncology community at large.